LX-P Phase 3 BRAND study

A Phase 3, Randomized, Double-blind, Double-dummy, Comparative Study of LX-P in Patients with Chronic Low Back Pain (BRAND)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222337

Enrollment

860

Registered

2013-12-21

Start date

2013-12-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Interventions

investigational material(s) Generic name etc : LX-P INN of investigational material : loxoprofen Therapeutic category code : 114 Antipyretics, analgesics and anti-inflammatory agents Dosage and Admini

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with well-defined as low back pain and judged as suitable for NSAIDs treatment, etc.

Exclusion criteria

Exclusion criteria: Patients with symptom(s)/finding(s) falling under the contraindications or relative contraindications stated in the package insert for tablet, pap, tape and gel formulations of loxoprofen sodium, etc.

Design outcomes

Primary

Measure	Time frame
Efficacy (pain assessment by patient)	—

Secondary

Measure	Time frame
Efficacy (overall assessment) Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026